Hsbc Holdings PLC Sells 44,302 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Hsbc Holdings PLC has reduced its stake in IQVIA Holdings Inc. by 10.6%, selling 44,302 shares, and now holds 372,079 shares valued at approximately $65.47 million.
• JPMorgan Chase & Co. and Pacer Advisors Inc. significantly increased their investments in IQVIA, with Pacer Advisors raising its position by 5,036.1% during the same quarter.
• IQVIA reported better-than-expected quarterly earnings, with an EPS of $2.81, surpassing estimates and showing a year-over-year revenue increase of 5.3%.

Hsbc Holdings PLC lowered its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 10.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 372,079 shares of the medical research company's stock after selling 44,302 shares during the period. Hsbc Holdings PLC owned 0.22% of IQVIA worth $65,465,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of IQV. Pacer Advisors Inc. raised its position in IQVIA by 5,036.1% in the 1st quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company's stock worth $153,681,000 after purchasing an additional 854,732 shares during the last quarter. JPMorgan Chase & Co. raised its position in IQVIA by 45.7% in the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company's stock worth $448,686,000 after purchasing an additional 798,534 shares during the last quarter. D. E. Shaw & Co. Inc. grew its holdings in IQVIA by 211.2% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 965,302 shares of the medical research company's stock worth $189,691,000 after acquiring an additional 655,153 shares during the period. Nuveen LLC acquired a new stake in IQVIA during the 1st quarter worth $76,328,000. Finally, Cadian Capital Management LP acquired a new stake in IQVIA during the 4th quarter worth $78,604,000. Institutional investors own 89.62% of the company's stock.

IQVIA Price Performance

Shares of IQV stock opened at $185.2190 on Friday. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $252.88. The firm has a market capitalization of $31.49 billion, a price-to-earnings ratio of 26.80, a price-to-earnings-growth ratio of 2.11 and a beta of 1.30. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. The firm has a fifty day moving average of $173.02 and a 200-day moving average of $168.57.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.04. The company had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm's revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on IQV shares. JPMorgan Chase & Co. lowered their target price on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a report on Monday, May 19th. Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. Cowen reaffirmed a "buy" rating on shares of IQVIA in a report on Wednesday, July 23rd. Mizuho lifted their target price on shares of IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. Finally, William Blair reaffirmed an "outperform" rating on shares of IQVIA in a report on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $228.62.

Insider Buying and Selling at IQVIA

In related news, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider directly owned 2,910 shares in the company, valued at $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.60% of the company's stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.